Join the Lupus Nephritis group to help and get support from people like you.
Lupus Nephritis News
Obinutuzumab Efficacious for Renal Response in Lupus Nephritis
WEDNESDAY, Feb. 26, 2025 – For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a...
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
THURSDAY, Feb. 20, 2025 – For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients...
Saphnelo Can Stave Off Organ Damage From Lupus
WEDNESDAY, Feb. 19, 2025 – Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital organs through inflammation. But a newer lupus drug appears t...
GSK Announces US FDA Approval of Benlysta (belimumab) for Pediatric Patients with Active Lupus Nephritis
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis London UK 27 July 2022 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and...
FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis
VICTORIA, British Columbia & ROCKVILLE, Md.-- January 22, 2021 – Aurinia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lupkynis (voclosporin) in...
FDA Approves GSK’s Benlysta as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
17 December 2020 -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus ...